Abstract
We retrospectively reviewed the clinical, hemodynamic, and echocardiographic data of 28 patients (17 men, 11 women; mean age, 36.3 y [range, 15-57 y]) who survived an average of 51.2 mos (range, 6-113 mos) after LVAD explantation. Patients were supported an average of 308.8 days (range, 21-872 days): 8 by a HeartMate XVE, 5 by a HeartMate IP, 6 by a Thoratec VAD, and 9 by a HeartMate II. Of the patients, 19 had idiopathic cardiomyopathy, 5 had ischemic cardiomyopathy, 3 had postpartum cardiomyopathy, and 1 had familial cardiomyopathy. Data were collected at LVAD implantation, during support, at device removal, and at follow-up evaluation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
